ReviewDrug design, development and therapy2022
The Role of Progesterone Receptors in Breast Cancer.
Review in Drug design, development and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 136 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
136 citing papers in PubMed, 1 synthesis or guideline pooled it, 217 citations in OpenAlex.
- Association of progesterone receptor status with breast cancer prognosis: a meta-analysis.World journal of surgical oncology · 2025Pooled it
- Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial.Signal transduction and targeted therapy · 2025Trial
- Targeting estrogen to the brain via DHED does not seem to protect against metabolic dysfunction in obese OVX mice.Endocrinology · 2026Article
- Evaluation of Camptothecin Through Computational and Experimental Approaches Targeting Membrane Receptors on Breast Cancer Cells for Potential Therapeutic Applications.International journal of molecular sciences · 2026Article
- Integrating delta radiomics and changes in multimodal ultrasound features for predicting response to neoadjuvant chemotherapy in breast cancer.Gland surgery · 2026Article
- Article
- Clinical impact ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Integrative multi-omics and network analysis identify potential targets of Chaihu Shugan Xiaozheng Formula in breast cancer.Translational oncology · 2026Article
- Alternative Splicing in Cyclin-Dependent Kinase 4/6 Inhibitor Resistance in Estrogen Receptor-Positive Breast Cancer.Drug development research · 2026Review
- Proteomic Biomarker Discovery in Breast Cancer: Advances, Challenges, and Translational Prospects.Journal of biochemical and molecular toxicology · 2026Review
- Molecular Mechanisms and Molecular Subtype-Specific Responses to Paclitaxel in Breast Cancer Cells.Molecules (Basel, Switzerland) · 2026Article
- Sex differences in non-reproductive cancers: mechanistic roles of sex-hormone signaling.Cell communication and signaling : CCS · 2026Review
- The relationship between different hormone receptors in breast cancer patients and ovarian response before chemotherapy; a retrospective cohort study.BMC women's health · 2026Article
- Effects of exposure to ethinyl estradiol during pregnancy and lactation on the postinvolution mammary gland.Journal of the Endocrine Society · 2026Article
- Anticancer Activity of Miswak Root Extract in Breast Cancer Cell Line: HRLC-MS/MS Profiling, In Vitro Evaluation, and In Silico Analysis.International journal of molecular sciences · 2026Article
- Low-progesterone receptor expression predicts nodal pathological complete response after neoadjuvant chemotherapy in premenopausal patients with ER-positive/HER2-negative breast cancer.Breast cancer (Tokyo, Japan) · 2026Article
- Biochemical alterations in endocrine and inflammatory pathways following breast cancer surgery: Laboratory evidence and clinical implications.Journal of medical biochemistry · 2026Article
- The Effect of Cannabidiol on Cancer-Pathway Genes in Doxorubicin-Sensitive and Resistant Breast Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2026Article
- A comparative in silico and in vitro analysis of antiviral agents targeting estrogen and progesterone receptors in breast cancer.Scientific reports · 2026Article
- Molecular mechanisms and therapeutic targeting implications of ER/mTOR signaling axis-driven tumor progression in aggressive meningiomas.Translational oncology · 2026Article
76 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The progesterone receptor (PR) modulates estrogen receptors α (ERα) action in breast cancer; it is an upregulated target gene of ER, and its expression is dependent on estrogen. PR is also a valuable prognostic biomarker in breast cancer, especially in hormone-positive breast cancer. High expression of PR is more frequently observed in tumors with a better baseline prognosis (ie, luminal A) than tumors with a poor baseline prognosis (ie, luminal B). In the following review, we present the role of PR in breast cancer, including the genomic characteristics and pathways in breast cancer, PR and endocrine therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.